ArticleThe lancet. Gastroenterology & hepatology2021
Metabolic-associated fatty liver disease in children and adolescents: Mexican experience.
Article in The lancet. Gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Metabolic Syndrome Prevalence and Its Components in Adolescents from Western Mexico.Pediatric reports · 2025Article
- Role of metabolic dysfunction-associated steatotic liver disease and of its genetics on kidney function in childhood obesity.International journal of obesity (2005) · 2025Article
- Impact of metabolic-associated fatty liver disease on the cholesterol efflux capacity of high-density lipoproteins in adolescents with type 2 diabetes.Frontiers in pediatrics · 2024Article
- Personalized Risk Assessment of Hepatic Fibrosis after Cholecystectomy in Metabolic-Associated Steatotic Liver Disease: A Machine Learning Approach.Journal of clinical medicine · 2023Article
- The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease.Therapeutic advances in endocrinology and metabolism · 2023Review
- MAFLD: what 2 years of the redefinition of fatty liver disease has taught us.Therapeutic advances in endocrinology and metabolism · 2022Review
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
34774158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.